Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Lendify in connection with new financing and redemption of bonds
Mandate

Vinge advised Lendify in connection with new financing and redemption of bonds

February 12, 2019 Banking and Finance

Lendify AB (“Lendify”), an online lender and one of Sweden’s most notable challengers in the banking sector, has secured new financing of up to SEK 1.000.000.000 from a large Swedish institution for the purpose of further financing its lending operations.

In connection with the new financing, Lendify’s two wholly owned subsidiaries, Lendify Sweden 1 AB and Lendify Sweden 2 AB, redeemed and de-listed their outstanding bonds from the Debt Securities list at the Nordic Derivatives Exchange.

Together with the management of the company, the institutional investor, the arranger and their legal advisors, Vinge has acted for Lendify in the structuring, documenting and execution of the transaction.

Vinge’s team mainly consisted of partner Albert Wållgren, associates Sebastian Frisk, Lionardo Ojeda and Axel Jansson (Banking and Finance) and partner Emma Stuart-Beck and associates Malin Haag and Caroline Krassén (Financial Services).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024